Streetbeat News

Stock Prices

FRD

FXNC

NE

PLAY

Several notable insider trades were reported, including significant purchases by insiders at Noble Corporation, Friedman Industries, Dave & Buster’s Entertainment, and First National Corporation. These trades may indicate confidence in the companies' prospects.

Portfolio Pulse from Avi Kapoor

July 08, 2024 | 12:12 pm

MDXH

MDxHealth has raised its FY24 revenue guidance from $83M-$85M to $85M-$87M, compared to the previous estimate of $84.048M.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 12:12 pm

LVO

LiveOne (NASDAQ:LVO) has joined the Russell 2000 Index and retired 4.2 million open market shares, reducing its total outstanding shares to 94.7 million. The company also registered 1.3 million warrants at $2.10 and plans to buy back $5 million worth of its shares.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 12:12 pm

WISA

WiSA Technologies has regained compliance with Nasdaq's listing requirements, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 12:06 pm

BILL

In the last three months, 10 analysts have published ratings on BILL Holdings (NYSE:BILL), with a mix of bullish, somewhat bullish, and indifferent sentiments. The average 12-month price target has decreased by 8.5% to $78.6. Several analysts have lowered their price targets and ratings, reflecting cautious sentiment.

Portfolio Pulse from Benzinga Insights

July 08, 2024 | 12:02 pm

ENPH

Enphase Energy has started U.S. shipments of its IQ8 commercial microinverters, supported by the Inflation Reduction Act, which aims to advance renewable energy and job creation.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 12:02 pm

RJF

Analysts have mixed views on Raymond James Financial (NYSE:RJF) with recent ratings showing 1 bullish and 3 indifferent stances. The average 12-month price target is $132.5, reflecting a slight increase from the previous $130.00. Key analysts have adjusted their ratings and price targets, indicating varied expectations for the company's future performance.

Portfolio Pulse from Benzinga Insights

July 08, 2024 | 12:02 pm

SNOW

The article provides a comprehensive analysis of Snowflake (NYSE:SNOW) based on 33 recent analyst reviews. The overall sentiment is predominantly bullish, with 26 out of 33 analysts rating it as either 'Bullish' or 'Somewhat Bullish'. The average 12-month price target is $206.67, showing a slight decline from the previous average of $212.50. Key analysts have maintained or adjusted their ratings and price targets, reflecting mixed but generally positive sentiment. Snowflake's financial performance shows strong revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

July 08, 2024 | 12:01 pm

MRUS

Merus N.V. has dosed the first patient in its Phase 2 trial of Petosemtamab for second-line metastatic colorectal cancer. The Biclonics therapy targets EGFR and LGR5.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 12:01 pm

ACET

Adicet Bio shares are trading higher after the company announced that the FDA granted it Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 11:57 am